Curanex Pharmaceuticals Inc. (CURX)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
CURX Chart
Curanex Pharmaceuticals Inc. (CURX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Curanex Pharmaceuticals Inc. ever had a stock split?
Curanex Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jun Liu CEO | NASDAQ (NMS) Exchange | 23126K106 CUSIP |
| US Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company focused on the discovery, development, and commercialization of innovative botanical drugs aimed at treating patients with inflammatory diseases. The company is engaged in research and development of various therapeutic solutions that address a wide range of health conditions. Initially founded in 1996 under the name Fordman Pharma Inc, the company underwent a rebranding in November 2023, adopting its current name, Curanex Pharmaceuticals Inc. The company is headquartered in Jericho, New York, and continues to advance its research with a commitment to improving patient outcomes.
Products and Services
- Phyto-N
Phyto-N is the flagship product of Curanex Pharmaceuticals Inc. This botanical drug is in various stages of development for several therapeutic applications, including treating ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. The diverse therapeutic areas highlight Phyto-N's potential to offer natural treatment options for patients suffering from both chronic and acute inflammatory diseases.
